publication date: Dec. 20, 2010
In this issue:
FDA approval of Abraxane sets stage for competition between taxane drugs. Abraxane a nanotechnology drug? Sponsor says yes, FDA says.
Also in this 8-page issue: NCI seeks $6.17 billion in “bypass” budget request, but faces shortfall in its actual budget.
NCI names 15 to Director’s Consumer Liaison Group.
SAIC-Frederick makes awards to proteomics research teams.
Latest state cancer statistics released.
Smokers may get cessation help from Medicare.
Funding opportunities listed.
Download (PDF 356KB)
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.